Isomorphic Labs, a drug discovery startup owned by Google‘s parent Alphabet, will have its first AI-designed drug enter clinical trials by the end of 2025, according to founder Demis Hassabis. Speaking at the World Economic Forum, Hassabis revealed that the company is targeting major disease areas, including oncology, cardiovascular, and neurodegeneration, as reported by the Financial Times.
Also Read: Novo Nordisk and Valo Health Expand AI Partnership for Drug Discovery
Collaborations with Eli Lilly and Novartis
The company, which was spun out of…